Palmitoylethanolamide, or PEA, is a signalling molecule made by the body that is also sold as a supplement. Pain research is substantial and often positive, but PEA is not a proven miracle cure and many online claims go beyond the evidence.
The best summary at present is that several randomised studies and meta-analyses find less pain on average among people taking PEA. At the same time, conditions, formulations, doses and study designs vary widely. There are also well-conducted studies in which PEA showed no benefit.
A 2025 meta-analysis combined 18 randomised trials with 1,196 participants and found an average reduction in pain in favour of PEA. A broader systematic review described 47 randomised trials and found the strongest evidence for pain and general wellbeing.
Results vary by condition. There are positive studies in diabetic neuropathic pain, for example, while a good study of neuropathic pain after spinal cord injury found no significant benefit.
PEA has more evidence behind it than an arbitrary supplement claim, but the findings are not consistent enough to call it a proven standard treatment for chronic or neuropathic pain.
Palmitoylethanolamide belongs to the N-acylethanolamines, a group of fatty signalling molecules formed in various body tissues. PEA is not the same as THC or CBD, although it interacts with some of the same biological regulatory systems.
PEA does not appear simply to suppress pain in the way a conventional painkiller might. Research mainly points to effects on processes involving inflammation, nerve excitability and immune cells. PPAR-alpha is often named as an important target. Mast cells, microglia, TRPV1 and other signalling pathways are also being studied.
The fact that a substance occurs naturally in the body does not tell us what extra amount is useful, which formulation works best or what long-term supplementation does. Those questions still require good research.
The average results are positive, but they need to be read with some caution. A standardised mean difference, or SMD, compares results from studies that use different pain scales. A larger absolute value means a larger average difference between groups, but it does not directly tell you how many points your pain score will fall.
18 randomised studies, 1,196 participants.
This is a clear positive signal at group level. It does not prove that every individual condition or every PEA formulation responds equally well.
An earlier meta-analysis of double-blind randomised trials included 11 studies with 774 participants and also found a benefit. Its authors concluded, however, that the optimal dose, formulation and area of use needed further study. Other reviews have noted major differences between studies and possible publication bias.
A reliable explanation does not show only studies that turned out well. Both kinds of result exist for PEA.
In a quadruple-blind, placebo-controlled trial, 70 participants received either 600 mg of PEA per day or placebo for eight weeks. Total neuropathic pain and pain interference improved significantly more in the PEA group. A 2026 meta-analysis also found a positive signal, but included only three studies with 188 participants. Results varied greatly and several studies used PEA as part of a combination product.
A double-blind multicentre study of ultramicronised PEA for neuropathic pain after spinal cord injury randomised 73 people. In the primary analysis of 68 participants, there was no significant difference in pain reduction: an average of -0.4 points with PEA versus -0.7 with placebo, p = 0.46.
Chronic pain is not a single condition. PEA studies involve different types of pain, diagnoses and participant groups. A positive average across several studies therefore cannot predict whether PEA works for one particular diagnosis.
PEA has been studied in different forms of neuropathic, nociceptive and nociplastic pain. Some studies are positive and others are not. That provides a general signal, but no guarantee for every pain problem, diagnosis or person.
If a diagnosis has not been studied separately in good research, results from other pain syndromes cannot simply be carried across. ACNES is one example: we found no good randomised clinical trial of PEA specifically for ACNES. Zorgfuik therefore does not claim that PEA works for it.
In a double-blind crossover study, 14 healthy volunteers used either 3 × 400 mg of PEA per day or placebo for four weeks. Several experimental measures of peripheral and central sensitisation moved in a favourable direction, including wind-up and allodynia.
Lang-Illievich et al., 2022 · Read Zorgfuik on central sensitisation.
A randomised study in fibromyalgia examined adding PEA 600 mg twice daily plus acetyl-L-carnitine to existing treatment with duloxetine and pregabalin. The add-on group improved more on several outcome measures.
Di Carlo et al., 2023 · Read Zorgfuik's fibromyalgia dossier.
Most clinical pain research concerns PEA taken by mouth. Studies use different formulations, including standard, micronised and ultramicronised PEA.
Topical PEA has been studied in people, but the evidence for local nerve pain is much thinner. A randomised study of 72 people with eczema found improvements in redness and dryness after four weeks compared with another cream. That is interesting for skin use, but it is not evidence that PEA ointment treats an entrapped nerve in ACNES.
Studies use different amounts and treatment periods. Knowing those can be useful, as long as research doses are not confused with personal advice.
Used for eight weeks in the randomised trial of diabetic neuropathic pain, among other studies.
Used in various pain studies, for example divided across two or three doses.
These also occur in research and practice publications. They do not establish one universal standard for everyone.
The 2025 meta-analysis found significant differences from about four to six weeks. That does not fit the picture of a conventional painkiller taken "as needed" for an immediate effect. Here too, study averages cannot predict how quickly one person might notice anything.
Randomised trials report few serious problems, and recent reviews describe PEA as generally well tolerated. But saying "PEA has no side effects" is too absolute.
Not all older studies recorded adverse events equally systematically. Large numbers of users and long follow-up are also needed to detect rare effects reliably. A modern study of respiratory infections, for example, reported diarrhoea in three PEA users and a rash in one participant; the placebo group had a similar number of reported events.
No major, well-confirmed medicine interactions stand out in the clinical literature. Even so, pharmacokinetics and interactions have been studied less extensively than they have for many licensed medicines. Saying it "can be combined with all medicines without problems" therefore goes beyond the evidence.
PEA dissolves poorly in water. Smaller particle sizes and other formulations have therefore been developed to improve absorption. In the broad review of 47 randomised trials, the strongest evidence often came from studies of micronised, ultramicronised or specially dispersible formulations. This does not prove that one commercial product is "the best": direct comparative studies are limited.
🔴 Not supported. We could not find a sound direct clinical study demonstrating this specific threefold difference. Without an original source, this claim does not belong on a healthcare website as fact.
🟠 Too categorical. PEA is generally well tolerated in studies, but research cannot guarantee zero side effects. Supplements can cause unwanted effects too.
🟠 Too broad. Old and modern studies have found a positive signal for upper respiratory tract infections. That does not justify a general claim that PEA prevents 40 to 60% of "all kinds of infections".
The infection claim does have a scientific origin. In a 2023 double-blind randomised trial, 426 participants received 300 mg of a PEA formulation twice daily or placebo for twelve weeks. The PEA group reported 39 episodes of upper respiratory tract infection, compared with 64 in the placebo group. Illness duration did not differ significantly.
The story that an Italian chemist discovered PEA in her kitchen is incorrect. PEA was identified by a different research group in 1957; Levi-Montalcini contributed to its scientific explanation decades later.
Research into anti-inflammatory components of substances including egg yolk led F.A. Kuehl Jr. and colleagues to identify N-(2-hydroxyethyl)-palmitamide, the substance now known as PEA, in 1957. They described it as a naturally occurring anti-inflammatory component.
Kuehl et al., Journal of the American Chemical Society, 1957.
Decades later, Italian Jewish neurologist Rita Levi-Montalcini played an important part in the renewed interest in PEA. In 1993, her research group described the ALIA principle, Autacoid Local Inflammation Antagonism, involving the local regulation of mast cells.
Under Mussolini's Fascist racial laws, Levi-Montalcini was barred from working normally at a university because she was Jewish. In her official Nobel autobiography, she writes that she built a small research unit at home and installed it in her bedroom. There she studied chick embryos and nerve development. This was unrelated to the original discovery of PEA.
Levi-Montalcini and Stanley Cohen received the Nobel Prize in Physiology or Medicine for their discovery of nerve growth factor, or NGF. Her later work on mast cells and local regulation of inflammation contributed to the modern line of PEA research.
In practice, PEA is both taken by mouth and applied locally. A person may notice a clear difference, no difference or be unable to tell which part of a combination had an effect. Such experiences are useful for asking questions and recognising patterns, but they do not replace controlled research.
You do not need to arrive with an internet leaflet and prove that PEA "works". These questions are more useful:
We mainly list systematic reviews, meta-analyses and randomised trials here. This is deliberate: commercial sales pages are not a suitable basis for medical claims.
View the broader treatment overview or continue reading about different pain contexts and diagnoses.
